The following companies represent the most notable insider
buys of the past week. In order to be considered for this list,
the stock had to:
� Be in at least one guru's portfolio,
� Have at least two insiders buying over 1,000 shares
� Have at least one transaction cost over $100,000.
Achillion Pharmaceuticals (
In the past week, two directors made
into Achillion Pharmaceuticals.
Director Jason Fisherman bought 10,000 shares at an average price
of $7.87 per share. This transaction cost Fisherman a total of
$78,700. Since his buy the price per share has increased
Director Dennis Liotta bought 20,000 shares this past week at an
average price of $7.91 per share. This buy cost the director a
total of $158,200. Liotta now owns at least 85,000 shares of
company stock. Since his buy the price per share has increased
These buys mark the first insider buys for Achillion since June
[size=13px; line-height: 1.22]Achillion is a biopharmaceutical
company that focuses on the discovery, development and
commercialization of innovative treatments for infectious
diseases. Within the anti-infective market, it is currently
concentrating on the development of antivirals for the treatment
of chronic hepatitis C and the development of antibacterials for
the treatment of resistant bacterial infections.[/size]
Recent happenings in Achillion:
The company announced at the end of May that their long-time
President and CEO Michael Kishbauch had decided to retire from
the company after nine years of services. Kishbauch has been
replaced by Milind Deshpande; the company saw a slight drop in
share prices as a result of this announcement.
The drop in prices was ultimately short-lived as the stock price
for Achillion has surged since its presentation at the 38
Annual Deutsche Bank Health Care Conference where the company
revealed its new drug, ACH-3422, which is designed to combat
hepatitis C. The company expects to unveil the preliminary
version of the drug in 2014 and begin human testing by the end of
on Achillion note that the company's revenue has been in decline
for the past three years.
Achillion Pharmaceuticals has a market cap of $800.4 million; its
shares were traded at around $8.21 with a P/B ratio of 8.9.
Paul Tudor Jones
is currently the only guru that holds stake in Achillion. As of
March 31, Jones held 23,217 shares representing 0.03% of his
total assets managed. The graph below shows Jones' holding
history of Achillion.
WESCO International (
During the past week WESCO International Vice President and CFO
made a significant buy into the company. Kenneth Parks bought
2,700 shares of company stock at an average price of $73.39 per
share. This cost the CFO a total of $198,153. Since his buy, the
price per share has decreased approximately -1.8%.
[size=13px; line-height: 1.22]The CFO made this buy as the price
of WESCO stock is at a 10-year high. [/size]
WESCO International is a provider of electrical, industrial and
communications maintenance, repair and operating (
) and original equipment manufacturers (OEM) products,
construction materials, and advanced supply chain management and
logistics services. Its product categories include general and
industrial supplies; wire, cable and conduit communications
products; power distribution equipment; lighting and controls and
control, automation and motors.
WESCO International has a market cap of $3.46 billion; its shares
were traded at around $72.07 with a P/E ratio of 15.90 and a P/S
ratio of 0.50. WESCO had an annual average earnings growth of
8.6% over the past 10 years.
The analysis on the company reports:
� The company's operating margin has been in decline
for the past five years. The average rate of decline per year is
� The P/S ratio is close to a five-year high of 0.59.
� The price is close to a 10-year high of $79.85.
According to the Peter Lynch Valuation Chart the stock appears to
There are currently nine gurus that hold stake in WESCO
International. Click here to see the holding history of the
Synta Pharmaceuticals (
In the past week there have been four insiders making large buys
into Synta Pharmaceuticals.
Director and 10% Owner Bruce Kovner made the largest buy of the
week, adding 2,000,000 shares to his holdings. The shares traded
for $4.64 each for a total transaction amount of $9,280,000.
Kovner now owns over 22 million shares of Synta.
President and CEO Safi Bahcall added 10,000 shares at $4.04 per
share. This cost Bahcall a total of $40,400. The CEO now owns
around 2.5 million shares of Synta. Since his buy, the price per
share has increased 12.13%.
Director Robert Wilson also added 10,000 shares; his shares
traded at $5 per share. This cost the director an even $50,000.
Wilson now owns approximately 700,000 shares of Synta. Since his
most recent buy, the price per share has dropped -9.4%.
Lastly, Senior VP and Chief Medical Officer Vojo Vukovic added
10,000 shares for an average price of $4.58. This buy cost the
vice president a total of $45.800. Vukovic now owns over 35,000
shares. Since his buy, the price per share has dropped around
These four buys come as the price dropped to a 52-week low.
Synta Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing and commercializing small molecule drugs
to extend and enhance the lives of patients with severe medical
conditions, including cancer and chronic inflammatory diseases.
Recent Happenings at Synta Pharmaceuticals:
The company saw a sharp decline in share prices as the company's
experimental lung cancer drug showed less benefit than
anticipated. The company fell 34% on June 3, the largest
single-day drop since February 2009.
The patients given the company's ganetespib treatment along with
docetaxel, a standard chemotherapy for lung cancer, had a 32%
increase in survival compared to those given docetaxel only,
Synta reported. George Zavoico, an analyst with MLV & Co. in
New York said, "The shorter survival result was considered a
disappointment by investors, leading to today's [June 3]
The financials on the company report that its revenue has been in
decline for the past three years.
Synta Pharmaceuticals has a market cap of $298.8 million; its
shares were traded at around $4.53 with a P/S ratio of 37.80 and
a P/B ratio of 2.8.
Jim Simons, Steven Cohen and Louis Moore Bacon all maintain
holdings in Synta Pharmaceuticals. Click here to see their
Calamos Asset Management (
Calamos Asset reported seven insider buys coming from six
different insiders this past week. These insiders consist of:
Director John Calamos, President and COO James Boyne, SVP and CFO
Nimish Bhatt, Director Richard Gilbert, Director Bradford Bulkley
and Director Nick Calamos.
These insiders bought a combined total of 77,980 shares in the
price range of $10.57 to $10.73.
[size=13px; line-height: 1.22]Calamos Investments is a
diversified global investment firm offering investment strategies
including equity, fixed income, convertible and alternative
investments. The firm offers strategies through separately
managed portfolios, mutual funds, closed-end funds, private funds
and UCITS funds. Clients include major corporations, pension
funds, endowments, foundations and individuals.[/size]
Recent Happenings at Calamos:
The company recently announced the launch of Calamos Long/Short
Fund (A Shares: CALSX; C Shares: CCLSX; I Shares: CILSX; R
Shares: CRLSX) as of June 2. The Calamos Long/Short Fund seeks to
achieve its investment objective of long-term capital
appreciation primarily by taking long and short positions in
equity securities of large and mid-cap U.S. companies.
Calamos Asset Management has a market cap of $220.7 million; its
shares were traded at $10.82 with a P/E ratio of 15.70 and a P/S
ratio of 0.70. The dividend yield of Calamos is 4.4%. The company
had an annual average earnings growth of 31.4% over the past five
The analysis on Calamos reports:
� The operating margin has been consistently
� The company has enough cash to cover all of its
� The dividend yield is close to a three-year high
� The P/B ratio is close to a three- year low of 0.99.
� The revenue has been in decline over the past year.
The company's historical dividend yield:
The Peter Lynch Valuation of the company shows that the company
appears to be fully valued:
Jim Simons and Mario Gabelli currently hold stake in Calamos.
View their holding histories here.
You can view all insider transactions here. Also check out
CEO/CFO insider buys and sells here.
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to